# Abatacept With Methotrexate- Phase IIB

> **NCT00162266** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 524 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Abatacept (BMS-188667)
- **DRUG:** Abatacept (BMS-188667)
- **DRUG:** Abatacept (BMS-188667)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00162266
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 524 (ACTUAL)
- **Last updated:** 2012-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162266, "Abatacept With Methotrexate- Phase IIB". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00162266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*